Noven announced the launch of Minivelle (estradiol transdermal system) 0.025mg/day, a new low dosage strength approved for the prevention of postmenopausal osteoporosis.

Minivelle 0.025mg/day patch is the smallest estrogen therapy patch currently available measuring at 1.65 square centimeters, which is about one-third smaller than Minivelle 0.0375mg/day. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism. Estrogens act to reduce the elevated concentrations of these hormones seen in postmenopausal women.

RELATED: Minivelle Patch Gains New Strength, New Indication

Minivelle was initially approved by the Food and Drug Administration (FDA) in 2012 for the treatment of moderate to severe vasomotor symptoms due to menopause. In September 2014, the FDA approved a new indication for the prevention of postmenopausal osteoporosis for all Minivelle doses. The new 0.025mg/day patch is approved for the prevention of postmenopausal osteoporosis only.

Minivelle is now available in 0.025mg/day, 0.0375mg/day, 0.05mg/day, 0.075mg/day, and 0.1mg/day strengths in 8-count packs.

For more information call or visit